Brought to you by CND Life Sciences

YOUR PATIENTS DESERVE OBJECTIVE ANSWERS. SO DO YOU.

Introducing the Syn-One Test

Brought to you by CND Life Sciences

YOUR PATIENTS
DESERVE
OBJECTIVE
ANSWERS.
SO DO YOU.

Introducing the Syn-One Test

The first commercially available test of its kind—applying world-class science and carefully honed laboratory techniques to accurately detect and visualize abnormal alpha-synuclein in cutaneous nerve fibers. All through a simple skin biopsy.

Order a free Syn-One Test Biopsy Kit

Advantages of the Syn-One Test:

High sensitivity and specificity*

Minimally invasive, convenient and simple

Visual proof of phosphorylated a-synuclein co-located in dermal nerves

Backed by 10 years of research by neurologists at leading institutions

Prior authorization conducted for each patient

Consistent payments from Medicare (CND is a participating provider)

Supports shared decision-making with patients

Achieve earlier diagnosis and detection

*The core methods of the Syn-One Test have demonstrated greater than 95% sensitivity and specificity based on results from an NIH-supported, prospective, multicenter, blinded study of 428 patients.

Gibbons CH, Levine T, Bellaire B, et al. The Synuclein-One Study: Skin biopsy detection of phosphorylated alpha-synuclein for diagnosis of synucleinopathies. Abstract presented at: American Academy of Neurology; April 26, 2023; Boston, Massachusetts.